メダゼパム

Medazepam

HCID 4041CAS 2898-12-6

基本情報

標準SMILES
CN1CCN=C(c2ccccc2)c2cc(Cl)ccc21
InChIKey
YLCXGBZIZBEVPZ-UHFFFAOYSA-N
分子式
C16H15ClN2
平均分子量
270.75 g/mol
単同位体質量
270.09237616

概要

Medazepam is an organic molecular entity.

名称と識別子

優先名称
Medazepam
IUPAC
7-chloro-1-methyl-5-phenyl-2,3-dihydro-1,4-benzodiazepine
現地名
メダゼパム
英語名
MEDAZEPAM
分子式
C16H15ClN2
分子量
270.76

名称と別名

medazepamPamnace2898-12-6MedazepamumDTXSID1048708P0J3387W3SDTXCID80286347-Chloro-1-methyl-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepineRefChem:810832N05BA03Ro 54556Ro 5 4556
名称をさらに表示
レスミット1-メチル-5-フェニル-7-クロロ-2,3-ジヒドロ-1H-1,4-ベンゾジアゼピン7-クロロ-2,3-ジヒドロ-1-メチル-5-フェニル-1H-1,4-ベンゾジアゼピンメザパムメダゼパムメダゼパム (JP17)パムネース7-クロロ-1-メチル-5-フェニル-2,3-ジヒドロ-1H-1,4-ベンゾジアゼピンSimanDiepinElbrusEsmailAnsilanmezapamMezepan
220-783-4ResmitNobriumRudotelEnobrinNiveltonNarsis7-Chloro-2,3-dihydro-1-methyl-5-phenyl-1H-1,4-benzodiazepine

データベース識別子

CAS
2898-12-6
PubChem CID
4041
DTXSID
DTXSID1048708
ChEMBL
CHEMBL28333
ChEBI
CHEBI:31807
UNII
P0J3387W3S
EC Number
220-783-4
Nikkaji
J2.167I

物性

構造計算による物性

XLogP
4.4
極性表面積
15.6 Ų
水素結合供与体数
0
水素結合受容体数
2
回転可能結合数
1
重原子数
19

実験および物理化学的性質

Drugs · 5 件

DEA NFLIS-Drug Category -> Benzodiazepines

DEA Schedule IV Controlled Substance -> Depressants

Pharmaceuticals

Pharmaceuticals -> Benzodiazepines

Pharmaceuticals -> Synthetic Cannabinoids or Psychoactive Compounds

SpringerMaterials PropertiesFusion temperature
Human DrugsPharmaceuticals
Collision Cross Section160.8 Ų [M+H]+ [CCS Type: TW; Method: Major Mix IMS/Tof Calibration Kit (Waters)]

物理化学的性質

融点
95 · 95-97°
沸点
420.36 °C · 420.36°C (rough estimate)
比重(密度)
1.1336 · 1.1336 (rough estimate)
屈折率
1.5749 · 1.5749 (estimate)
貯蔵温度
-20 °C · -20°C
溶解性
Methanol (Slightly), Water (Slightly)

安全と法規制

GHS分類

GHS Classification · 4 件

Warning

H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]

P203, P260, P261, P263, P264, P270, P271, P280, P301+P317, P304+P340, P318, P319, P330, P403+P233, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 31 reports by companies from 3 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

危険有害性情報

Regulatory InformationDEA schedule IV controlled substance
Other Safety InformationIMAP assessments - 1H-1,4-Benzodiazepine, 7-chloro-2,3-dihydro-1-methyl-5-phenyl-: Environment tier I assessment
Hazard Classes and CategoriesAcute Tox. 4 (100%)

毒性情報

Treatment · 1 件

General supportive measures should be employed, along with intravenous fluids, and an adequate airway maintained. Hypotension may be combated by the use of norepinephrine or metaraminol. Dialysis is of limited value. Flumazenil (Anexate) is a competitive benzodiazepine receptor antagonist that can be used as an antidote for benzodiazepine overdose. In particular, flumazenil is very effective at reversing the CNS depression associated with benzodiazepines but is less effective at reversing respiratory depression. Its use, however, is controversial as it has numerous contraindications. It is contraindicated in patients who are on long-term benzodiazepines, those who have ingested a substance that lowers the seizure threshold, or in patients who have tachycardia or a history of seizures. As a general rule, medical observation and supportive care are the mainstay of treatment of benzodiazepine overdose. Although benzodiazepines are absorbed by activated charcoal, gastric decontamination with activated charcoal is not beneficial in pure benzodiazepine overdose as the risk of adverse effects often outweigh any potential benefit from the procedure. It is recommended only if benzodiazepines have been taken in combination with other drugs that may benefit from decontamination. Gastric lavage (stomach pumping) or whole bowel irrigation are also not recommended.

Toxicity Summary · 1 件

Benzodiazepines bind nonspecifically to benzodiazepine receptors BNZ1, which mediates sleep, and BNZ2, which affects affects muscle relaxation, anticonvulsant activity, motor coordination, and memory. As benzodiazepine receptors are thought to be coupled to gamma-aminobutyric acid-A (GABAA) receptors, this enhances the effects of GABA by increasing GABA affinity for the GABA receptor. Binding of the inhibitory neurotransmitter GABA to the site opens the chloride channel, resulting in a hyperpolarized cell membrane that prevents further excitation of the cell.

Carcinogen ClassificationNo indication of carcinogenicity to humans (not listed by IARC).

安全データ

wgk
WGK 2
ridadr
3249
毒性
LD50 in mice (mg/kg): 360 i.p., 1070 orally (Randall)
risk_code
22
hazard_code
Xn
hazard_class
6.1(b)

化学と産業

薬理情報

ATC Code · 2 件

N - Nervous system

QN - Nervous system

MeSH Pharmacological Classification · 5 件

Drugs used to prevent SEIZURES or reduce their severity.

Drugs used to induce drowsiness or sleep or to reduce psychological excitement or anxiety.

A heterogeneous group of drugs used to produce muscle relaxation, excepting the neuromuscular blocking agents. They have their primary clinical and therapeutic uses in the treatment of muscle spasm and immobility associated with strains, sprains, and injuries of the back and, to a lesser degree, injuries to the neck. They have been used also for the treatment of a variety of clinical conditions that have in common only the presence of skeletal muscle hyperactivity, for example, the muscle spasms that can occur in MULTIPLE SCLEROSIS. (From Smith and Reynard, Textbook of Pharmacology, 1991, p358)

Agents that alleviate ANXIETY, tension, and ANXIETY DISORDERS, promote sedation, and have a calming effect without affecting clarity of consciousness or neurologic conditions. ADRENERGIC BETA-ANTAGONISTS are commonly used in the symptomatic treatment of anxiety but are not included here.

Substances that do not act as agonists or antagonists but do affect the GAMMA-AMINOBUTYRIC ACID receptor-ionophore complex. GABA-A receptors (RECEPTORS, GABA-A) appear to have at least three allosteric sites at which modulators act: a site at which BENZODIAZEPINES act by increasing the opening frequency of GAMMA-AMINOBUTYRIC ACID-activated chloride channels; a site at which BARBITURATES act to prolong the duration of channel opening; and a site at which some steroids may act. GENERAL ANESTHETICS probably act at least partly by potentiating GABAergic responses, but they are not included here.

用途と製造

Use ClassificationPharmaceuticals
応用分野 · 3 件

解説7-chloro-2,3-dihydro-1-methyl-5-phenyl-1H-1,4-benzodiazepine.C16H15ClN2(270.76).2-アミノ-5-クロロベンゾフェノンに塩化アルミニウムの存在下,エチレンイミンを反応させ,ベンゾジアゼヒン骨格を合成したのち,N-メチル化すると得られる."白色の結晶.融点95~97 ℃.クロロホルムに易溶,エタノールに可溶,水に不溶.ジアゼパムと同様に精神安定剤としての作用が強く,催眠鎮静剤,抗不安剤として使用される.LD50 1070 mg/kg(マウス,経口).[CAS 2898-12-6]森北出版「化学辞典(第2版)

用途バルビツール酸誘導体です。 中枢神経系に作用し、特に脳幹網様体賦活系 に対する抑制作用を示します。作用時間は長 時間です。

使用Tranquilizer (minor).

関連反応

6 件

関連ノート

読み込み中…